{
  "id": "6402c71f201352f04a00000a",
  "type": "summary",
  "question": "What is the mechanism of action of daridorexant?",
  "ideal_answer": "Daridorexant is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist that is being developed for the treatment of insomnia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
    "http://www.ncbi.nlm.nih.gov/pubmed/35298826",
    "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
    "http://www.ncbi.nlm.nih.gov/pubmed/35426136"
  ],
  "snippets": [
    {
      "text": "Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35426136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daridorexant (Quviviq\u2122; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}